News

Zacks Investment Research on MSN3d

Exelixis Gains 15.6% YTD: How Should You Play the Stock?

Exelixis’ EXEL year-to-date performance has been good. Shares of the biotech company have gained 15.6% compared with the ...

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III ...
IEEE4d

A Survey on Self-Supervised Learning: Algorithms, Applications, and ...

Deep supervised learning algorithms typically require a large volume of labeled data to achieve satisfactory performance. However, the process of collecting and labeling such data can be expensive and ...
Targeted Oncology5d

Sacituzumab Tirumotecan Shows Promising Antitumor Activity with Manageable Toxicity in Solid Tumors

A phase 1/2 trial reveals sacituzumab tirumotecan shows manageable toxicity and promising antitumor activity in patients with ...

PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

The UK’s cartographer maps mission to help people and business

Feature Britain's Ordnance Survey (OS), founded in 1791, is interloping in the digital age. Minecraft, AR gaming, and EV ...

A guy in California is suing Microsoft for discontinuing Windows 10, demanding free extended support

When you buy through links on our articles, Future and its syndication partners may earn a commission.